DrugPatentWatch Database Preview
Investigational Drug Information for Ipatasertib
Email this page to a colleague
What is the drug development status for Ipatasertib?
Ipatasertib is an investigational drug.
There have been 48 clinical trials for Ipatasertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and National Cancer Institute (NCI).
There are one hundred and sixty-seven US patents protecting this investigational drug and one international patent.
Summary for Ipatasertib
| US Patents | 167 |
| International Patents | 1,785 |
| US Patent Applications | 546 |
| WIPO Patent Applications | 414 |
| Japanese Patent Applications | 190 |
| Clinical Trial Progress | Phase 2 (2020-12-01) |
| Vendors | 49 |
Recent Clinical Trials for Ipatasertib
| Title | Sponsor | Phase |
|---|---|---|
| Pembrolizumab Alone or in Combination With Ipatasertib for the Treatment of Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | National Cancer Institute (NCI) | Phase 2 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer | National Cancer Institute (NCI) | Phase 1 |
| A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer | Foundation Medicine | Phase 1/Phase 2 |
Clinical Trial Summary for Ipatasertib
Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib
US Patents for Ipatasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ipatasertib | ⤷ Sign up for a Free Trial | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Sign up for a Free Trial |
| Ipatasertib | ⤷ Sign up for a Free Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Sign up for a Free Trial |
| Ipatasertib | ⤷ Sign up for a Free Trial | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Sign up for a Free Trial |
| Ipatasertib | ⤷ Sign up for a Free Trial | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ipatasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ipatasertib | Argentina | AR107432 | 2036-01-11 | ⤷ Sign up for a Free Trial |
| Ipatasertib | Australia | AU2017207268 | 2036-01-11 | ⤷ Sign up for a Free Trial |
| Ipatasertib | Australia | AU2019203280 | 2036-01-11 | ⤷ Sign up for a Free Trial |
| Ipatasertib | Australia | AU2021201018 | 2036-01-11 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
